Botanix Pharmaceuticals Ltd has released a press release.
Dermatology Industry Leader Joins Botanix
Filed with ASX ·
Watch Botanix Pharmaceuticals' latest callBotanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings Call · Replay · Mar 2Read the transcript of Botanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings Call6ix hasn’t read this filing yet.
Botanix Pharmaceuticals Limited on 6ix
Earlier from Botanix Pharmaceuticals
- Botanix Provides Retraction in Presentation
- Pause In Trading
- Permetrex Outperforms Other CBD Topical Products
- Investigators Meeting Completed for BTX 1204 Phase 2 Study
- Ethics Approval for Phase 2 Atopic Dermatitis Study Received
Later from Botanix Pharmaceuticals
- Pause in Trade
- Study Confirms Anti-inflammatory and Other Properties of CBD
- BTX 1801 Kills Superbugs Without Resistance World-First
- Botanix Antimicrobial Platform Addresses Global Threat
- Botanix $40 Million US Lead Placement and Management Update
Follow Botanix Pharmaceuticals into a list and get an email when it puts out news.
Follow Botanix Pharmaceuticals